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Abstract 
Introduction: Approximately 20-30% of patients with Ulcerative Colitis (UC) require surgery, 
the majority of these being elective due to chronic symptoms refractory to medical 
treatment. The decision for surgery is difficult and dependant on patient preferences. Current 
resources for patients considering surgery have been found not to meet minimum 
international standards. The overall aim of the ‘DISCUSS’ study is to develop and evaluate a 
new Patient Decision Aid (PtDA) for patients considering surgery for UC created in line with 
international minimum standards. 
Methods and analysis: This is a prospective mixed-methods study of adults (18+ years) who 
are considering surgical intervention for UC across two regional centres in Yorkshire, UK. This 
study is in 3 stages. In stage 1 we will develop the PtDA and its content via systematics reviews 
and a patient questionnaire. In stage 2 we will assess the face validity of the PtDA using mixed-
methods on key stakeholders using both semi-structured interviews and questionnaires, 
following which the PtDA will be refined. In stage 3 we will assess the acceptability of using 
the PtDA in clinical practice. This will use a mixed-methods approach on clinicians and patients 
who are considering undergoing elective surgery. Questionnaires including the Preparation 
for Decision Making Scale, a measure of anxiety and decisional conflict will be analysed at 2 
timepoints using paired sample t-tests and confidence intervals. Interviews with patients and 
clinicians will be analysed using thematic analysis. 
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Ethics and Dissemination: Research Ethics approval from North East – Tyne & Wear South 
Research Ethics Committee(Ref: 19/NE/0073) and Health Research Authority approval (Ref: 
257044) have been granted. Results will be published in open access peer-reviewed journals, 
presented and conferences and distributed through the Crohn’s and Colitis UK charity. 
External endorsement will be sought from the International Patient Decision Aid Standards 
(IPDAS) Collaboration inventory of PtDAs. 
Article summary; 
Strengths and limitations of this study: 
● This study will develop and evaluate a new patient decision aid for patients 
considering surgery for ulcerative colitis which will meet minimum international 
standards. This is a preliminary pilot study. 
● This study will provide evidence for its acceptability and value to patients in routine 
clinical practice when considering surgery for ulcerative colitis. 
● This study will also provide evidence of the acceptability of the patient decision aid 
from the clinicians’ perspective and the feasibility of use in routine clinical practice. 
● This study will not provide evidence on the value of the PtDA nationally. However, it 
will provide evidence across two large regional centres in Yorkshire which may be 
utilised to form the study design of a national evaluation. 
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INTRODUCTION 
The rationale for the study 
Ulcerative colitis (UC) is a chronic, relapsing and remitting inflammatory condition of the colon 
and rectum. It causes debilitating symptoms such as bleeding per rectum, increased stool 
frequency, abdominal pain and tenesmus (1). Symptoms can be managed using medical 
therapies such as aminosalicylates, corticosteroids, biologics agents (anti-tumour necrosis 
factor-α or anti-integrin) and tofacitinib (2-5). However approximately 20-30% of patients with 
UC will require surgery during their disease course (6). A minority of patients will require 
emergency surgery – but the majority of patients have elective surgery due to chronic 
symptoms, refractory to medical treatment (7). Individuals therefore make a choice, or series 
of choices, to continue with medical treatment or undergo surgery. Surgery may be 
undertaken with the intention of proceeding to further reconstructive surgery to restore 
continuity of the gastrointestinal tract, or remaining with a permanent ileostomy. 
  
The decision to opt for elective surgery is described as preference-sensitive as the preferred 
treatment option is dependent on patient preferences due to clinical equipoise between the 
options (8). The same can be said for the decision between reconstructive surgery versus 
permanent ileostomy. The impact on lifestyle of these two choices cannot be understated – 
reconstructive surgery will avoid a stoma, with an acceptance of potential complications such 
as increased stool frequency, pouchitis or faecal incontinence (9). A stoma may offer more 
control over excretory functions, but is associated with complications such as parastomal 
hernia, as well as psychological sequelae (10,11). When selecting a treatment option, it is 
clear that the patient must select the option based on their preferences. 
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Shared decision-making is a process whereby clinicians share information about treatment 
options, empowering the patient to make a decision based on their preferences (12). 
Providing clear and balanced pre-operative information is a major prerequisite to informed 
decision making (12,13). National Institute for Health and Care Excellence (NICE) guidelines 
for UC emphasise the importance of providing such information, but note that no high quality 
studies assessing the desired content of information were available on which to base 
recommendations (14). As such clinicians lack guidance on patient informational preferences 
on which to base discussions during consultations. Clinician preferences can be misaligned 
with patient preferences, especially when considering surgical options for UC (15), forming a 
barrier to decision-making in this population. Pre-operative discussions may also be limited 
by ‘implicit persuasion’ – a process whereby clinicians subconsciously place greater emphasis 
on treatment options they believe are suited to the patient (16). Lack of time in clinic, as well 
as the lack of guidance on the content of pre-operative consultations, may provide limitations 
in the shared decision-making process for UC patients (17). 
 
Patient decision aids 
Patient decision aids (PtDAs) are specially created tools which aim to improve patient 
knowledge and aid decision-making (18,19). They are evidenced based, utilising the most up-
to-date clinical evidence, studies assessing patient informational preferences and evidence 
on how patients make decisions (20). PtDAs can be used within the clinical encounter, by the 
clinician, to provide structure to consultations, but also by the patients outside the encounter 
to aid their deliberation – a key step to informed consent (13).  
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A systematic review of PtDAs in surgery has illustrated their role in improving knowledge, 
reducing decisional conflict and increasing patient input into decision making (21). A 
satisfactory PtDA for patients considering surgery for UC is not currently available. The single 
aid registered on the Decision Aids Library Inventory (22) does not meet minimum standards 
laid out by the International Patient Decision Aid Standards (IPDAS) (23), which have 
established clear guidance for the systematic development of a PtDA (24). This can be 
summarised into 3 stages, as previously described by members of our research group (25), 
and forms the methodology behind this protocol. It is therefore proposed that a new PtDA 
for patients considering surgery for UC, created in-line with minimum standards, will work 
towards filling an informational need for both patients and clinicians (14,26). 
Aims and objectives 
The aim of this research is to develop, assess and validate a patient decision aid for patients 
considering elective surgery for ulcerative colitis; i.e. whether to continue with their current 
medical treatment, or whether to undergo surgery. This will also include information on the 
different surgical options (mainly permanent stomas vs reconstructive surgery) as this may 
influence the overall decision to undergo surgery. We will do this in line with the systematic 
development process specified by IPDAS, ensuring the decision aid meets minimum standards 
(24,27). 
The study objectives are to:  
1. Develop a decision aid for use by gastroenterology and colorectal surgery teams 
(consultant surgeons/gastroenterologists, stoma/IBD nurses) to support adult 
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patients (>18 years of age) in their decision about elective surgery, and the surgical 
option they may wish to opt for. 
2. Assess the face validity of the decision aid to support patients make an informed 
decision about their preferred treatment option. 
3. Pilot an evaluation study for the acceptability of the decision aid in clinical practice. 
This will use a mixed methods approach to capture the views of: 
a. patients making the treatment decision and 
b. gastroenterology and colorectal surgery health professionals supporting the 
patient through their decision. 
It is anticipated the evaluation of the PtDA will determine whether the administration of a 
PtDA in the treatment pathway will better support patients in their treatment decisions, as 
well as providing structure and guidance to consultations with patients.  
METHODS AND ANALYSIS 
The methodology used for this research has been adapted from a previously published 
protocol to develop a PtDA for women with cancer to help them make fertility preservation 
treatment decisions (Cancer, Fertility and Me), led by a member of our research team (GLJ) 
and funded by Yorkshire Cancer Research (S391) (25). The protocol also follows established 
guidance from IPDAS and other recommended guidance regarding the development of PtDA 
(24,27). The study process is summarised in figure 1. 
A steering group with relevant expertise to support PtDA development is essential (24). 
Therefore, a steering group was created prior to protocol development and submission for 
grant funding to ensure all stakeholders were represented. The steering group consists of; 
specialist surgical and gastroenterology clinicians, health psychologists with expertise in 
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decision-making, IBD/Stoma nurses, a medical student, and patient representatives. All 
sections of the protocol have been reviewed and discussed by the steering group. The PtDA 
will be developed across two regional centres (Sheffield Teaching Hospitals and Hull and East 
Yorkshire Hospitals). The steering group will hold regular meetings during stage 1 to decide 
the content and design of the aid, and will hold regular meetings at important stages 
thereafter. Ethics approval was granted on 13th March 2019. 
Design 
Stage 1: Development of the PtDA 
1.    Validating patient informational preferences 
Our group has already carried out qualitative work exploring patient informational 
preferences when considering surgery (26). These results will be validated on a national scale 
by a questionnaire using established methodology (15,28). Questionnaire content will include 
demographic data, the control preferences scale (29) and questions about the preferred 
content and format of pre-operative information. This will provide a description of whether 
particular demographic groups of patients are amenable to a PtDA, and the preferred content 
and format of such an aid. Questionnaires will be disseminated to a number of sites through 
an established network of IBD researchers. Prior to questionnaire development, patients will 
be involved in questionnaire design and refinement via a focus group held at Sheffield 
Teaching Hospitals. This will help make the findings generalisable and ensure key concepts 
are included within the questionnaire. 
2.       Synthesising the best available evidence 
This will consist of the following stages: 
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a) Systematic reviews of evidence about the risks and benefits of elective surgery and 
continued medical management will be undertaken, as well as a systematic review on 
factors influencing treatment choices. A full list of inclusion and exclusion criteria for 
each review is listed in Supplementary appendix (Table S1, S2, S3): 
● A systematic review of outcomes after surgery to inform the PtDA using the 
best available evidence. This has been registered on the PROSPERO 
(www.crd.york.ac.uk/PROSPERO) database (ref: 
CRD42018115513).Methodology will include the procedures subtotal 
colectomy with permanent end ileostomy, proctocolectomy, ileal-anal pouch 
anastomosis and ileorectal anastomosis. Ileorectal anastomosis will be 
included in the PtDA as our research group notes it is a procedure that is 
offered in some UK centres, as well as in centres outside the UK. Its inclusion 
is with the caveat that some centres may not offer this operation, and this will 
be noted in the aid. Primary outcome will be quality of life, with secondary 
outcomes covering a wide range of early and late complications after surgery. 
● Systematic review of risks and benefits of continued medical treatment. This 
will inform the decision aid so that the consequences of continued medical 
treatment – positive and adverse – can be quantified for patients facing this 
choice. This has been registered on PROSPERO (ref: CRD42019126186). 
● Systematic review of the factors that may facilitate or hinder patients with UC 
to make medical and surgical treatment choices (e.g. possible fear of a stoma) 
to ensure these elements are captured and addressed in the new resource. 
This has been registered on PROSPERO (ref: CRD42019125193). 
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b) Focus groups with expert clinicians, nurses and patients regarding the optimum time 
to introduce the PtDA into the treatment pathway, as well as the optimum content 
for each group. This will be via a PPI day at Sheffield Teaching Hospitals. 
3. Drafting the PtDA 
Once the evidence has been synthesised, the steering group will meet to decide the content 
of the aid. The PtDA will be created using IPDAS guidance (24,27); including guidance on 
balancing options (30), risk presentation (30–33), eliciting patient values (34), use of patient 
stories (18),  and enabling readability (35,36), something found to be poor in the UC patient 
literature (23).  
The content of the aid will be guided by the informational preferences studies and systematic 
reviews of evidence we complete. Significant risks, benefits and outcomes, and their 
associated probabilities from our systematic reviews will be included. Common topics of 
informational preferences will be discussed by the group, and a consensus established on the 
inclusion. The composition of the group, with both expert clinicians and patients, will help to 
develop content that meets the requirements of both patients and healthcare professionals. 
Stage 2: Face validity study 
The aim of this stage is to assess the PtDA for comprehension, feasibility and acceptability 
using key stakeholders - sometimes referred as learner verification or alpha testing (24,37). 
This will be done with both clinicians and patients, using qualitative methodology, and 
according to an established protocol, with which we have extensive experience. This will be 
undertaken across two large sites (Sheffield and Hull). 
Sample 
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A purposive sample of healthcare professionals and patients not involved in the steering 
group will be invited to take part in the study. Purposive sampling has been chosen to ensure 
recruitment of a representative sample of both healthcare professionals and patients. The 
HCP sample will include colorectal surgeons, gastroenterologists, IBD nurses and Stoma 
nurses. The patient sample will include those who opted for surgery, those who considered 
but declined surgery and those currently deliberating treatment options. We expect a sample 
size of 20 participants, with a minimum of 10 healthcare professionals and 10 patients, will 
be enough based on previous studies and experience (25). However, sample size will be 
guided by data saturation, which is in-line with good qualitative methods (38–40). 
Recruitment 
Patients will be identified through the services at the two clinical centres by clinicians and 
nurses. We will also advertise stage 2 of the study through the Crohn’s and Colitis UK forums. 
Following this the contact details for consenting patients will be passed on to a trained 
researcher and those willing to participate will be sent the PtDA for review. Healthcare 
professionals will be recruited from the study sites through purposive sampling. All contact 
details will be stored securely at either Sheffield Teaching Hospitals or Leeds Beckett 
University. 
Data collection 
Qualitative 
Consenting clinicians and patients will be posted the PtDA and given 1-2 weeks to assess the 
aid, with a telephone interview taking place at the end of the time period. Patients and 
clinicians will provide verbal feedback on the aid, focussing on its comprehensibility and ease 
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of use. An interview schedule will be created a priori by expert members of the steering group. 
Interviews will be audio recorded, digitalised, and transcribed for analysis. 
Quantitative  
Patients will also be asked to complete a Preparation for Decision-Making Questionnaire. The 
Preparation for Decision-Making Questionnaire is a 10-item measure which will provide a 
score on a scale of 0-100 (41). The higher the score, the higher the perceived levels of 
preparation for decision-making - which will provide a validated quantitative measure of how 
individuals view the usefulness of the PtDA (41).  
Data analysis 
Interviews will be transcribed and coded using NVivo 11 Computer-Assisted Qualitative Data 
Analysis Software (QSR International, Australia). Analysis will use an inductive thematic 
approach, outlined by Braun and Clarke using a systematic five-step approach: familiarisation, 
generating initial codes, searching for themes, reviewing themes, and defining and naming 
themes (40). The themes actively generated by the researchers from the data will be 
discussed by the steering group. 
The steering group will subsequently refine the aid based on the results of this stage. If there 
are significant changes required, a second face validity study will be undertaken before 
progression to stage 3. 
Stage 3: Evaluation study  
The aim of this pilot is to field test the PtDA in clinical practice, as there may be clinical 
contextual factors impacting the PtDA. This is typically referred to as beta testing (24). This 
will follow a mixed-methods approach across the same two sites as in stage 2. We aim to 
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recruit 15 patients at each site for a minimum sample size of 30 – comparable with other PtDA 
pilots in the literature (42). A summary of stage 3 is provided in figure 2. 
Quantitative 
Sample and recruitment: All patients over the age of 18 that receive consultation about the 
possibility of undergoing elective surgery will be included. This includes consultations with 
clinicians and specialist nurses. We will use the referral model for implementing PtDA - a 
process where the clinician mentions the PtDA to eligible patients during consultation about 
treatment options, and indicates the clinical researchers will discuss the study following the 
consultation should the patient consent to involvement (43). Eligible patients identified by 
the clinical team will be invited to participate by the researcher(s) with the clinical team 
immediately following the consultation if they are present, or within a week if the patient 
consents to contact outside the clinical setting by a member of the research team. 
Data measures and collection: Patients will be asked to complete a series of questionnaires 
at baseline (1st clinic appointment) before administration of the PtDA. Patients will be 
instructed not to open or view the PtDA before completion of the questionnaires at baseline. 
Patients will then complete the same questionnaires at time-point 1 (immediately before the 
2nd clinic appointment). Questionnaires will include a measure of anxiety (STAI-6) (44), Stage 
of Decision-Making (45) and Decisional Conflict Scale (46) as recommended by IPDAS (24). All 
questionnaires will provide a quantitative measure to allow comparison before and after use 
of the PtDA. 
Analysis: Summary statistics will be reported for demographics and other relevant indicators. 
For decisional outcome measures we will use paired sample t-tests to calculate mean changes 
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from baseline to time-point 1. Confidence intervals will be set at 95% a priori, meaning values 
will be significant if p≤0.05.  
Qualitative  
Sample and recruitment: Healthcare professionals and patients will be asked to take part in 
semi-structured interviews. We will undertake 10 interviews with patients and 10 with 
healthcare professionals (IBD/stoma nurses, gastroenterology and surgical clinicians), 
although this will be guided by data saturation, in line with established protocols in qualitative 
research (38,40). The interviews will give a deeper insight into the experience of using the aid 
from a patient and clinician perspective in clinical practice. Clinician interviews will also 
explore views regarding the timing of the aid in the treatment pathway, establishing if the 
time previously eliciting in stage 1 is also the optimum time for additional sites. Patients will 
be recruited using purposive sampling from the sample of 30 that have taken part in the 
quantitative analysis of stage 3. Prior to interview patients will receive an information sheet, 
and on the day of interview the patient will be issued a consent form which will be co-signed 
with the interviewer.  
Data collection: An interview transcript will be created by expert members of the steering 
group a priori. Questions will be adapted from the transcript used in stage 2, with additional 
questions to add depth and clarity into the interpretation of the quantitative results. 
Questions will also focus on the PtDAs usefulness in helping the patient decide between 
treatment options.  
Analysis: All interviews will be transcribed and coded as per the same methods in stage 2. 
Framework analysis, an analysis designed specifically for applied health and policy research 
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(47), will be utilised to identify recurrent themes. Recurrent themes will be discussed with the 
steering group and subsequent refinement of the PtDA will take place. 
Patient and Public Involvement 
A patient representative who had prior experience of the decision at question in our PtDA 
was recruited to the steering committee prior to protocol development. Our representative 
contributed to overall protocol development, particularly the feasibility of stage 3 to the 
public. It was anticipated our patient representative would contribute heavily to the design 
and format of the PtDA, commenting on readability, layout and presentation of information.  
Patient representative did not contribute to study recruitment. Patients will also be involved 
in questionnaire development (stage 1) and design via a focus group.  
ETHICS AND DISSEMINATION 
Ethical considerations 
Research Ethics approval from North East – Tyne & Wear South Research Ethics Committee 
(Ref: 19/NE/0073) and Health Research Authority approval (Ref: 257044) has been granted. 
Written, signed consent will be obtained from all participants at stages where it is necessary. 
Participants will have the right to withdraw from the research process at any time throughout 
the study. All interviews will be kept strictly confidential and patients and healthcare 
professionals will be given a study ID number to maintain this confidentiality. Participation in 
this study will not interfere with usual patient care.  
Dissemination 
This a multidisciplinary, collaborative project with clinicians and patients. This will allow us to 
disseminate the research and its milestones into both the NHS and the wider healthcare 
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community through a variety of local, national and international forums such as charities and 
international meetings. We will also seek to index an online version of the PtDA in the Decision 
Aid Library Inventory once we have completed and analysed the paper version. We will also 
seek to index the NHS library of decision aids.  A web-based version of the PtDA will also allow 
dissemination through the internet which is widely accessible to patients worldwide. Social 
media such as twitter and blogs can also be utilised to signpost the availability of the 
instrument to both clinicians and patients.   
We plan to impact the academic and clinical community more widely through a combination 
of conference presentations and peer-reviewed publications. 
The primary output of this study is the PtDA, available in print. This will then be evaluated for 
effectiveness in a larger study, outside the costings of this grant application. Once fully 
evaluated it will be promoted more widely through social media, charity websites, 
professional organisations and academic sources. 
 
Figure 1: Summary of the study stages 
Figure 2: Summary of stage 3 – Evaluation study 
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